COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,026 Articles (22,627 medRxiv, 8,399 bioRxiv)

Most recent first Previous |  Page 115: Articles 1141-1150  | Next

Manipulation of Host Cholesterol by SARS-CoV-2
Doyle, A., Goodson, B. A., Kolaczkowski, O. M., Liu, R., Jia, J., Wang, H., Han, X., Ye, C., Bradfute, S. B., Kell, A. M., Rosas Lemus, M., Pu, J.
10.1101/2024.11.13.623299 — Posted: 2024-11-14
Modeling the SARS-CoV-2 Epidemic and the Efficacy of Different Vaccines Across Different Network Structures
Hartvigsen, G., Dimitroff, Y.
10.1101/2024.11.12.24317192 — Posted: 2024-11-13
Descriptive epidemiology of COVID-19 outcomes in England, from September 2023 to April 2024
Abdul Aziz, N., Allen, H., Assaraf, K., Dabrera, G., Ramsay, M., Allen, A.
10.1101/2024.11.12.24317146 — Posted: 2024-11-13
A roadmap to account for reporting delays for public health situational awareness: a case study with COVID-19 and dengue in United States jurisdictions.
Lopez, V. K., Bastos, L. S., Codeco, C., Johansson, M. A.
10.1101/2024.11.09.24315999 — Posted: 2024-11-13
Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-up
Carazo, S., Skowronski, D. M., Brousseau, N. M., Guay, C.-A., Sauvageau, C., Racine, E., Talbot, D., Ionescu, I. G., Fafard, J., Gilca, R., Phimmasone, J., De Wals, P., De Serres, G.
10.1101/2024.11.13.24317190 — Posted: 2024-11-13
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial
Wolfe, C. R., Cohen, J., Mahoney, K., Holmes, A., Betancourt, N., Gupta, D., Tosh, K., Narayan, K., Campanaro, E., Katz, C., Phelan, A.-M., Yalcin, I., Wingertzahn, M., Hawn, P., Schmidt, P., Li, Y., Popejoy, M.
10.1101/2024.11.11.24317127 — Posted: 2024-11-13
Dynamic metabolic modeling of ATP allocation during viral infection
Lu, A., Dukovski, I., Segre, D.
10.1101/2024.11.12.623198 — Posted: 2024-11-13
Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain
Li, P., Faraone, J. N., Hsu, C. C., Chamblee, M., Liu, Y., Zheng, Y.-M., Xu, Y., Carlin, C., Horowitz, J. C., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Jones, D., Li, J., Gumina, R. J., Bednash, J. S., Xu, K., Liu, S.-L.
10.1101/2024.11.12.623078 — Posted: 2024-11-13
Metaproteomics reveals age-specific alterations of gut microbiome in hamsters with SARS-CoV-2 infection
Creskey, M., Angulo, F. S., Wu, Q., Tamming, L., Fekete, E., Cheng, K., Ning, Z., Wang, A., Rodrigues, P. B., Rodovalho, V. d. R., Vinolo, M. A. R., Figeys, D., Li, X., Trottein, F., Zhang, X.
10.1101/2024.11.12.623292 — Posted: 2024-11-13
Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage
Powers, C., Williams, B., Kreher, A., Gao, F., West, B., Chupp, D., Allen, R.
10.1101/2024.11.11.623127 — Posted: 2024-11-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).